Navigation Links
Neurologix Announces First Quarter 2011 Financial Results
Date:5/13/2011

ble future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At March 31, 2011, the Company had cash and cash equivalents of approximately $5.4 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan of operations after October 31, 2011 and to repay the promissory notes issued in 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations. The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully receive approval from the FDA on its Investigational New Drug Application to commence a Phase 1 clinical trial for the treatment of epilepsy.
  • There is no assurance as to when, or if, the Company will be able to successfully complete the required preclinical testing of its gene therapy for the treatment of depression or Huntington's disease to enable it to file an Investigational New Drug Application with the FDA for permission to begin a Phase 1 clinical trial or that, if filed, such permission will be granted.

  • Other factors and assumptions not identified above could also cause the actual results to
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Neurologix Completes Additional $7 Million Financing
    5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
    6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
    7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
    8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
    9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
    10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
    11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/29/2015)... May 28, 2015 Research and Markets ... Jain PharmaBiotech,s new report "Cardiovascular Drug Delivery ... offering. Drug delivery to the cardiovascular ... because of the anatomy and physiology of the ... all organs of the body. Drugs can be ...
    (Date:5/29/2015)... and BOSTON , May ... in instrument development, custom automation, and contract manufacturing, and ... the Nanopatch™ needle-free drug delivery technology, have been named ... of the Nanopatch Jet Coating Instrument , an ... research and product development.  The award was announced last ...
    (Date:5/29/2015)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and the ... commercializing proven cancer therapies in new orphan drug ... American Association of Cancer Research (AACR) Advances in ... for its lead product candidate VAL-083 ...
    Breaking Medicine Technology:Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 2Global Cardiovascular Drug Delivery Market 2015 - Technologies, Markets and Companies 3Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 2Invetech And Vaxxas Named Recipients Of The 2015 Good Design Award For Development Of Nanopatch Jet Coating Instrument For Needle-Free Drug Delivery 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 2DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 3DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 4DelMar Pharmaceuticals Presents Additional Data on the Potential of VAL-083 in the Treatment of Temozolomide-Resistant Glioblastoma Multiforme 5
    ... VILLAGE, Nev., Nov. 2 PDL BioPharma, Inc. (PDL) ... on its previously disclosed $300 million securitization transaction intended ... royalties. Morgan Stanley & Co. Incorporated acted as ... terms of the securitization transaction, PDL sold to QHP ...
    ... Nov. 2 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... 30, 2009 on Monday, November 9, 2009, following the close of ... conference call at 5:00 p.m. Eastern Time on the same day ... call will be available for two weeks following the event. ...
    Cached Medicine Technology:PDL BioPharma Announces Closing of $300,000,000 Securitization Transaction 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 2Alexza to Announce 2009 Third Quarter Financial Results and Update Its AZ-004 NDA Status on Monday, November 9, 2009 3
    (Date:5/30/2015)... (PRWEB) May 30, 2015 AVT, the ... quality assurance, is joining forces with leading proofing solutions ... to the worldwide printing market. , Under ... new software engine for its offline inspection solutions, which ... printing industry and its varying production workflow setups and ...
    (Date:5/30/2015)... 30, 2015 The results of a ... has a high potential to cause mesothelioma, regardless of ... now on the Surviving Mesothelioma website. , ... Medicine in Lodz, Poland found that, among the 138 ... 1970 and 2012, all of them happened at plants ...
    (Date:5/30/2015)... May 30, 2015 EHO offers a ... Portal that gives hospices the ability to manage their ... of this business model, EHO has been able to ... to its clients and survive among the giants of ... management systems three years ago, it has simplified the ...
    (Date:5/30/2015)... 30, 2015 Cyclist Barry Haarde ... for the World 2015: Piles of Miles” near ... awareness about hemophilia and encourage individuals to support ... , Save One Life supports nearly 1,200 impoverished ... countries through direct sponsorships, scholarships and micro-enterprise grants. ...
    (Date:5/30/2015)... 30, 2015 This year the ... Pulmonary Horizons to offer one of the most diverse ... discuss successful practices to diagnose, treat and manage patients ... Pulmonary Horizons Conference is Interaction with Multidisciplinary Healthcare ... Overall Needs of Patients with COPD," said Brian W. ...
    Breaking Medicine News(10 mins):Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 2Health News:AVT and Global Vision Collaborate to Offer Cutting-edge Offline Inspection Solutions for Printing Industry 3Health News:New Study Finds Close Link Between Crocidolite Asbestos and Deadly Mesothelioma, According to Surviving Mesothelioma 2Health News:Barry Haarde Cycles 4,000 Miles Across the USA for Hemophilia 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 2Health News:Pulmonary Horizons 2nd Annual COPD Conference Miami Hilton Downtown, July 17-19, 2015 Patient Centered Cross-Continuum Education to Improve the Care of Patients with COPD 3
    ... culture than nonaccredited facilities, according to a new study ... Joint Commission Journal on Quality and Patient Safety . ... more than 4,000 facilities across the U.S. identify Joint ... issues such as staffing, teamwork, training, nonpunitive responses to ...
    ... 27 (HealthDay News) -- Two genetic variations are linked to ... according to new research. Glaucoma affects about 2.2 million ... said in a news release. "Loss of vision from ... irreversible damage to the optic nerve," noted one expert, Dr. ...
    ... , FRIDAY, April 27 (HealthDay News) -- Electrocardiograph ... risk for sudden cardiac death, according to a new study. ... conducted EKGs on 586 of them based on medical history, ... were found to have a heart disorder known to cause ...
    ... , THURSDAY, April 26 (HealthDay News) -- Medicare, the federal ... hurtling toward the critical list, but most people don,t want ... new Harris Interactive/HealthDay poll finds. Eighty-three ... Medicare affordable and sustainable, and 51 percent think that "a ...
    ... , FRIDAY, April 27 (HealthDay News) -- Children who are ... the time they are 12 years old, according to a new ... and the United Kingdom said its findings, published online April 27 ... risk for this type of behavior. Examples of self-harming ...
    ... from the Research Institute of Wildlife Ecology (FIWI) of ... analysed a capture-recapture data set on common dormice ( ... this species. These small rodents are about the size ... ), but, unlike their rodent cousins, they hibernate ...
    Cached Medicine News:Health News:NYUCN's Dr. Laura Wagner: Study finds accreditation improves safety culture at nursing homes 2Health News:Research Gets Closer to Genetic Roots of Glaucoma 2Health News:Heart Test Spots Sudden Death Risk in Young Athletes 2Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 2Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 3Health News:Americans Support Medicare Reform, But Not on Their Dime: Poll 4Health News:Bullied Children at Greater Risk for Self-Harm, Study Finds 2Health News:When to have kids: A complex question for hazel dormice 2
    Spurling-Kerrison (Colclough) Laminectomie Rongeur. 15 cm - 6, thick footplate, large handle, 40 up-cutting, jaws 3 mm wide....
    Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide....
    ... The Tangent Posterior Impacted Instrument Set offers ... of the advantages offered by the Tangent ... preparation and the ability to reproduce the ... to ensure proper vertebral body distraction. A ...
    Regulates physiological flow within normal ranges of Intraventricular Pressure (IVP) in the supine, sitting or standing position....
    Medicine Products: